Phase II evaluation and plasma pharmacokinetics of high-dose intravenous 6-thioguanine in patients with colorectal carcinoma

@article{Konits1982PhaseIE,
  title={Phase II evaluation and plasma pharmacokinetics of high-dose intravenous 6-thioguanine in patients with colorectal carcinoma},
  author={Philip H. Konits and Merrill J. Egorin and David A. Van Echo and Joseph Aisner and Paul A. Andrews and Matthew E. May and Nicholas R. Bachur and Peter H. Wiernik},
  journal={Cancer Chemotherapy and Pharmacology},
  year={1982},
  volume={8},
  pages={199-203}
}
A phase II study of intermittent high-dose 6-thioguanine (6-TG) was undertaken in 19 patients with metastatic colorectal carcinoma. Fourteen patients had received prior myelosuppressive therapy. 6-TG was administered as a single dose by IV bolus over 15–30 min, with retreatment every 3 weeks. The starting dose was 700 mg/m2 in ten patients, 900 mg/m2 in one patient, 1,000 mg/m2 in four patients, and 1,200 mg/m2 in two patients. Two patients received reduced doses (350 mg/m2) because of liver… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 11 extracted citations

References

Publications referenced by this paper.
Showing 1-9 of 9 references

6-Thioguanine (TG): A phase I study of intermittent oral (PO) and intravenous (IV) therapy in solid tumors (ST). Southeastern Cancer Group Study

  • A Denes, C Presant
  • Proc Am Assoc Cancer Res
  • 1979
3 Excerpts

Phase II trials with procarbazine, streptozotocin, 6-thioguanine and CCNU in patients with metastatic cancer of the large bowel

  • J Horton, A Mittelman, +5 authors JA Hanley
  • Cancer Chemother Rep 59:333-340
  • 1975
1 Excerpt

Similar Papers

Loading similar papers…